The Relationship Between the Expression of circFAT1 and Immune Cell in Patients with Non-Small Cell Lung Cancer

Figures & data

Figure 1 Case collection flow chart.

Figure 2 The expression level of circFAT1 in NSCLC tissues was analyzed by Ualcan database.

Table 1 Relationship Between circFAT1 Expression and Clinicopathological Features

Clinicopathologic Feature	Number	circFAT1
		High Expression Group (n=48)	Low Expression Group (n=48)	x^2	P
Age (years)
≥55	43	20	23	0.379	0.538
<55	53	28	25
Gender
Male	50	28	22	1.503	0.220
Female	46	20	26
Smoking history
Yes	45	18	27	3.388	0.066
No	51	30	21
Drinking history
Yes	47	19	28	3.376	0.066
No	49	29	20
Pathological type
Squamous carcinoma	45	26	19	2.050	0.152
Adenocarcinoma	51	22	29
Lymphatic metastasis
No	44	10	34	24.168	<0.001
Yes	52	38	14
TNM staging
Stage I-II	49	13	36	22.051	<0.001
Stage III-IV	47	35	12
Differentiated degree
Poorly differentiated	54	41	13	33.185	<0.001
Medium and high differentiation	42	7	35

Table 2 CD4+, CD8+ and Foxp3+ Were Positively Expressed in the Tissues [n (%)]

Group	Number	CD4+		Foxp3+		CD8+
		Positive Expression	Negative Expression	Positive Expression	Negative Expression	Positive Expression	Negative Expression
NSCLC group	96	52 (54.17)	44 (45.83)	54 (56.25)	42 (43.75)	41 (42.71)	55 (57.29)
Paracancerous group	96	1 (1.04)	95 (98.96)	2 (2.08)	94 (97.92)	92 (95.83)	4 (4.17)
X^2	–	67.788		68.168		63.641
P	–	<0.001		<0.001		<0.001

Table 3 Correlation Between the Expression of CD4+, Foxp3+ and CD8+ and Clinicopathological Characteristics

Clinicopathologic Feature	Number	CD4+				Foxp3+
		Negative Expression Group (n=44)	Positive Expression Group (n=52)	x^2	P	Negative Expression Group (n=42)	Positive Expression Group (n=54)	x^2	P
Age (years)
≥55	43	21	22	0.283	0.595	20	23	0.241	0.623
<55	53	23	30			22	31
Gender
Male	50	24	26	0.197	0.657	18	32	2.547	0.111
Female	46	20	26			24	22
Smoking history
Yes	45	23	22	0.950	0.330	23	22	1.866	0.172
No	51	21	30			19	32
Drinking history
Yes	47	20	27	0.399	0.528	20	27	0.054	0.817
No	49	24	25			22	27
Pathological type
Squamous carcinoma	45	21	24	0.024	0.878	17	28	1.228	0.268
Adenocarcinoma	51	23	28			25	26
Lymphatic metastasis
No	44	27	17	7.892	0.005	26	18	7.768	0.005
Yes	52	17	35			16	36
TNM staging
Stage I-II	49	28	21	5.156	0.023	30	19	12.419	<0.001
Stage III-IV	47	16	31			12	35
Differentiated degree
Poorly differentiated	54	18	36	7.768	0.005	16	38	10.000	0.002
Medium and high differentiation	42	26	16			26	16

Table 4 Association of CD8+ Expression with Clinicopathological Features

Clinicopathologic Feature	Number	CD8+
		Negative Expression Group (n=55)	Positive Expression Group (n=41)	x^2	P
Age (years)
≥55	43	22	21	1.196	0.274
<55	53	33	20
Gender
Male	50	28	22	0.071	0.790
Female	46	27	19
Smoking history
Yes	45	29	16	1.771	0.183
No	51	26	25
Drinking history
Yes	47	30	17	1.609	0.205
No	49	25	24
Pathological type
Squamous carcinoma	45	27	18	0.254	0.614
Adenocarcinoma	51	28	23
Lymphatic metastasis
No	44	15	29	17.870	<0.001
Yes	52	40	12
TNM staging
Stage I-II	49	20	29	11.103	0.001
Stage III-IV	47	35	12
Differentiated degree
Poorly differentiated	54	36	18	4.434	0.035
Medium and high differentiation	42	19	23

Data Sharing Statement

The original contributions presented in the study are included in the article.